AcZon is aware of the versatility of the technology and of the possibilities offered even in fields different from diagnosis and research in immunofluorescence.

 

Nanotechnologies, thanks to their intrinsic features due to the size, are considered highly promising in different fields such as in vivo diagnosis, theranostics and target therapy. The ductility of the AcZon nanoparticles has been highlighted with preliminary in vivo studies leading, for example, to a positive evaluation of the technology as multimodal tool for in vivo multiparametric diagnosis.

 

Fluorescent nanoparticles ad hoc modified to bind radioisotopes and then bounded to targeting molecules, have been inoculated into small animal models. The data collected confirm that the recognizing features of the system are maintained even in vivo.

 

The double revelation method allows to confirm, after post mortem analysis in quantitative fluorescence, what seen during microPET (positron emission tomography) in vivo.

 

 

REFERENCE

Chen et al. Mol. Pharmaceutics, 2014, 11 (11), pp 4007–4014

Accomasso et al. Stem Cells International,2016,  vol. 2016, Article ID 7920358, 23 pages

Harrison et al. RSC Adv., 2019, 9, 3176–3184

Chen et al  Chem Mater. 2017 October 24; 29(20): 8766–8779

Ahman et al. Journal of Physics: Conf. Series 1082 (2018) 012047

Pellegrino C, et al. (2018) J Nanomater Mol Nanotechnol S6: 003.

Benezra M, et al. J Clin Invest. 2011;121(7):2768–2780.